KR20180095647A - 신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 - Google Patents
신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 Download PDFInfo
- Publication number
- KR20180095647A KR20180095647A KR1020187020408A KR20187020408A KR20180095647A KR 20180095647 A KR20180095647 A KR 20180095647A KR 1020187020408 A KR1020187020408 A KR 1020187020408A KR 20187020408 A KR20187020408 A KR 20187020408A KR 20180095647 A KR20180095647 A KR 20180095647A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- component
- disease
- reducing agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010029148 Nephrolithiasis Diseases 0.000 title claims abstract description 21
- 208000000913 Kidney Calculi Diseases 0.000 title claims abstract description 20
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- 238000011282 treatment Methods 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 239000004575 stone Substances 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000006568 Urinary Bladder Calculi Diseases 0.000 claims abstract description 11
- 229960003067 cystine Drugs 0.000 claims abstract description 11
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 10
- 230000034005 thiol-disulfide exchange Effects 0.000 claims abstract description 10
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- 239000002775 capsule Substances 0.000 claims description 26
- 239000003826 tablet Substances 0.000 claims description 24
- -1 alkali metal salt Chemical class 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000003113 alkalizing effect Effects 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 230000002485 urinary effect Effects 0.000 claims description 10
- 229940127557 pharmaceutical product Drugs 0.000 claims description 9
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 claims description 8
- 239000001508 potassium citrate Substances 0.000 claims description 8
- 229960002635 potassium citrate Drugs 0.000 claims description 8
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 8
- 235000011082 potassium citrates Nutrition 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 150000003573 thiols Chemical group 0.000 claims description 5
- 210000000626 ureter Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 206010011778 Cystinuria Diseases 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000008240 homogeneous mixture Substances 0.000 claims description 4
- 229960001639 penicillamine Drugs 0.000 claims description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 229960000830 captopril Drugs 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 229960001790 sodium citrate Drugs 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 230000000116 mitigating effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract description 2
- 150000001342 alkaline earth metals Chemical class 0.000 abstract description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000003932 urinary bladder Anatomy 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000028394 ureteral disease Diseases 0.000 description 4
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 208000012931 Urologic disease Diseases 0.000 description 2
- 208000029162 bladder disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004402 tiopronin Drugs 0.000 description 2
- 208000026533 urinary bladder disease Diseases 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 229940097633 capoten Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940064774 cuprimine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940028870 thiola Drugs 0.000 description 1
- LWRYDHOHXNQTSK-UHFFFAOYSA-N thiophene oxide Chemical compound O=S1C=CC=C1 LWRYDHOHXNQTSK-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271020P | 2015-12-22 | 2015-12-22 | |
| US62/271,020 | 2015-12-22 | ||
| US201562272894P | 2015-12-30 | 2015-12-30 | |
| US62/272,894 | 2015-12-30 | ||
| PCT/US2016/067466 WO2017112574A1 (en) | 2015-12-22 | 2016-12-19 | Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180095647A true KR20180095647A (ko) | 2018-08-27 |
Family
ID=59064032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187020408A Withdrawn KR20180095647A (ko) | 2015-12-22 | 2016-12-19 | 신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170172960A1 (enExample) |
| EP (1) | EP3393469A4 (enExample) |
| JP (1) | JP2019504024A (enExample) |
| KR (1) | KR20180095647A (enExample) |
| AU (1) | AU2016378399A1 (enExample) |
| CA (1) | CA3009332A1 (enExample) |
| WO (1) | WO2017112574A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018285927B2 (en) * | 2017-06-16 | 2023-04-20 | Altibio, Inc. | Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders |
| US20190282525A1 (en) * | 2018-03-19 | 2019-09-19 | Cronus Research Labs Private Limited | Tiopronin oral composition |
| WO2020092402A1 (en) * | 2018-10-30 | 2020-05-07 | Harrow Health, Inc. | Pharmaceutical compositions of tiopronin and methods for preparing thereof |
| US20220016078A1 (en) * | 2020-07-14 | 2022-01-20 | GyanRx Sciences, Inc. | Methods Of Treating Kidney Stones |
| US20240254098A1 (en) * | 2021-05-10 | 2024-08-01 | Altibio, Inc. | Thioester prodrugs for the treatment of renal anomalies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050025839A1 (en) * | 2003-07-28 | 2005-02-03 | Polli James Edward | Formulation approach to enhance transporter-mediated drug uptake |
| CN100361653C (zh) * | 2004-09-29 | 2008-01-16 | 上海华源医药科技发展有限公司 | 硫普罗宁软胶囊 |
| AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
| CN1833637A (zh) * | 2005-03-16 | 2006-09-20 | 安徽龙科马生物制药有限责任公司 | 一种新的硫普罗宁冻干粉制剂及其制备方法 |
| CN1698594A (zh) * | 2005-04-25 | 2005-11-23 | 中国药科大学 | 硫普罗宁的缓释制剂 |
| CN101062024B (zh) * | 2006-04-25 | 2012-11-07 | 刘祥华 | 一种硫普罗宁组合药物及其制备方法 |
| FR2967578B1 (fr) * | 2010-11-18 | 2012-12-28 | Advicenne Pharma | Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie |
| US8916609B2 (en) * | 2011-06-10 | 2014-12-23 | New York University | Compounds as L-cystine crystallization inhibitors and uses thereof |
| CN102516143B (zh) * | 2012-01-06 | 2013-11-20 | 刘全胜 | 一种硫普罗宁无菌粉及其制剂与制备方法 |
| WO2014145195A1 (en) * | 2013-03-15 | 2014-09-18 | Cerovene, Inc. | Pharmaceuticals comprising a ph-dependent component and ph-raising agent |
-
2016
- 2016-12-19 JP JP2018532419A patent/JP2019504024A/ja active Pending
- 2016-12-19 EP EP16879926.0A patent/EP3393469A4/en not_active Withdrawn
- 2016-12-19 US US15/383,211 patent/US20170172960A1/en not_active Abandoned
- 2016-12-19 CA CA3009332A patent/CA3009332A1/en not_active Abandoned
- 2016-12-19 WO PCT/US2016/067466 patent/WO2017112574A1/en not_active Ceased
- 2016-12-19 KR KR1020187020408A patent/KR20180095647A/ko not_active Withdrawn
- 2016-12-19 AU AU2016378399A patent/AU2016378399A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3393469A4 (en) | 2019-09-25 |
| CA3009332A1 (en) | 2017-06-29 |
| WO2017112574A1 (en) | 2017-06-29 |
| JP2019504024A (ja) | 2019-02-14 |
| US20170172960A1 (en) | 2017-06-22 |
| EP3393469A1 (en) | 2018-10-31 |
| AU2016378399A1 (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ballatori et al. | N-acetylcysteine as an antidote in methylmercury poisoning. | |
| CA2506930C (en) | Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer | |
| KR20180095647A (ko) | 신장결석 치료용 약학적 제제 및 이의 제조방법 및 이용방법 | |
| RU2392926C2 (ru) | Оральная композиция для абсорбции фосфорных соединений | |
| FI87528C (fi) | Foerfarande foer framstaellning av en oral dosenhet av kaliumklorid | |
| RU2002106748A (ru) | Фармацевтические соли трамадола | |
| CN101528218A (zh) | 治疗粘膜炎的组合物和方法 | |
| US20090075950A1 (en) | Dosage Forms Containing A PPI, NSAID And A Buffer | |
| JPS5857315A (ja) | 製薬学的調製物 | |
| WO2011008976A1 (en) | N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen | |
| DE102014008685A1 (de) | Freisetzungssystem für therapeutisches Gas | |
| ES2946237T3 (es) | Sistemas de dos componentes que comprenden ácido acetilsalicílico y una sal de carbonato | |
| HUE032753T2 (en) | A pharmaceutical composition comprising a hydrogen carbonate salt and its use as a medicament for the treatment and / or prevention of urinary and related diseases | |
| JP2021073275A (ja) | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 | |
| ES2946260T3 (es) | Sistemas de dos componentes que comprenden ácido acetilsalicílico y una sal de fosfato | |
| RU2354378C1 (ru) | Комбинированный противотуберкулезный препарат | |
| DK165966B (da) | Forbedret piroxicamholdigt anti-inflammatorisk praeparat | |
| DK166343B (da) | Forbedret piroxicamholdigt laegemiddel | |
| KR100367877B1 (ko) | 구연산칼륨을 주제로 한 요로결석 치료제중 분말 및 미립제형 의 제조방법 | |
| RU2247560C1 (ru) | Комбинированный состав с противотуберкулёзным действием | |
| RU2247559C1 (ru) | Противотуберкулёзное средство | |
| RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием | |
| KR102619489B1 (ko) | 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물 | |
| RU2201230C1 (ru) | Лекарственное средство флузол, обладающее противогрибковым действием | |
| JP6521968B2 (ja) | 吸着ヨウ素および／または吸着ヨウ化物塩を含む活性炭とナトリウム／ヨウ化物共輸送体阻害剤とを含む肺機能を改善するための組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180716 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20200422 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PC1203 | Withdrawal of no request for examination |